摘要
目的探究强化剂量阿托伐他汀对不稳定型心绞痛患者介入治疗(PCI)术后心肌炎症反应的影响。方法选取2012年1月—2014年1月焦作煤业(集团)有限责任公司中央医院接收治疗的不稳定型心绞痛患者88例,随机分为治疗组(44例)和对照组(44例)。治疗组患者PCI术前口服阿托伐他汀钙片80 mg/d,术后口服40 mg/d。对照组患者术前口服20mg/d,术后口服20 mg/d阿托伐他汀钙片。比较两组患者术前、术后SOCS1 mRNA、蛋白表达、血清干扰素-γ(IFN-γ)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)等炎症因子的表达。结果术后治疗组SOCS1mRNA、蛋白表达均较治疗前显著升高,治疗前后差异有统计学意义(P<0.05);且治疗后治疗组这两者的表达均高于对照组,两组比较差异有统计学意义(P<0.05)。术后两组IFN-γ、hs-CRP、TNF-α、IL-10水平均较术前有所提高,同组治疗前后差异有统计学意义(P<0.05);术后,治疗组IFN-γ、hs-CRP、TNF-α显著低于对照组,而IL-10水平高于对照组,两组比较差异有统计学意义(P<0.05)。结论强化剂量阿托伐他汀可以通过上调SOCS1的表达,并调节炎症因子IFN-γ、hs-CRP、TNF-α、IL-10水平从而减轻不稳定型心绞痛介入治疗术后的心肌炎症反应。
Objective To investigate the influence of strengthening dosage atorvastatin in the treatment of myocardial inflammation after PCI patients with unstable angina. Methods Collecting 88 cases suffered from unstable angina in Jiaozuo Coal Industry Group Central Hospital from January 2012 January 2014, which were randomly divided into treatment （44 cases） and control （44 cases） group. The patients in the treatment group were po administered with Atorvastatin Tablets, 80 mg/d before PCI, then 40 mg/d after PCI. The patients in the control group were po administered with Atorvastatin Tablets, 20 mg/d before PCI, then 20 mg/d after PCI. Expression of SOCS1 mRNA and protein, inflammatory cytokine such as IFN-γ, hs-CRP, TNF-α, and IL-10 in the two groups were compared. Results After the treatment, the expression of SOCS1 mRNA and protein in the treatment group was increased significantly, and the difference was statistically significant before and after the treatment （P〈0.05）. And after the treatment the two indicators of the treatment group were higher than those of control group, and there were differences between the two groups （P 〈0.05）. After the treatment, the levels of IFN-γ, hs-CRP, TNF-α, IL-10 in the two groups were significantly increased, and the differences were statistically significant before and after the treatment in the same group （P 〈 0.05）. After the treatment, IFN-γ, hs-CRP and TNF-αin the treatment group was significantly lower than those in the control group, while IL-10 was higher than that in the control group, and there were differences between the two groups （P〈0.05）. Conclusion Atorvastatin in strengthening dosage can increase the expression of SOCS1 and modulate inflammatory factors such as IFN-γ, hs-CRP, TNF-α, and IL-10 so as to reduce myocardial inflammation of patients with unstable angina after PCI.
出处
《现代药物与临床》
CAS
2014年第10期1125-1128,共4页
Drugs & Clinic
基金
首都医科大学基础临床合作课题(13JL44)
